{"id":"NCT01143064","sponsor":"BHR Pharma, LLC","briefTitle":"Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients With Severe Traumatic Brain Injury","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2014-03","completion":"2014-03","firstPosted":"2010-06-14","resultsPosted":"2024-10-02","lastUpdate":"2024-10-02"},"enrollment":1195,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Brain Injuries"],"interventions":[{"type":"DRUG","name":"Progesterone","otherNames":["BHR-100"]},{"type":"DRUG","name":"Lipid emulsion without progesterone","otherNames":[]}],"arms":[{"label":"Progesterone","type":"ACTIVE_COMPARATOR"},{"label":"Lipid emulsion without progestrone","type":"PLACEBO_COMPARATOR"}],"summary":"The SyNAPSe trial will study if giving intravenous (i.v.) progesterone within 8 hours of the injury for a total of 120 hours to severe traumatic brain injury patients improves their recovery.","primaryOutcome":{"measure":"Glasgow Outcome Scale (GOS)","timeFrame":"6 months","effectByArm":[{"arm":"BHR-100","deltaMin":189,"sd":null},{"arm":"Placebo","deltaMin":183,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":156,"countries":["United States","Argentina","Austria","Belgium","China","Czechia","Finland","France","Germany","Hungary","Israel","Italy","Malaysia","Netherlands","Romania","Russia","Singapore","Spain","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["17011666","18447940","25493978"],"seeAlso":["http://www.synapse-trial.com"]},"adverseEventsSummary":{"seriousAny":{"events":224,"n":596},"commonTop":["Pyrexia","Anaemia","Hypertension","Hypokalaemia","Constipation"]}}